Do Bcl-2 and survivin help distinguish benign from malignant B-cell lymphoid aggregates in bone marrow biopsies?

Journal of Clinical Laboratory Analysis

Volumn 18, Issue 6, 2004, Pages 285-288

  Gandhi, Amish M ^a   Ben Ezra, Jonathan M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Apoptosis; Immunohistochemistry; Lymphoma

Indexed keywords

CD20 ANTIBODY; MONOCLONAL ANTIBODY CD3; PROTEIN BCL 2; SURVIVIN;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BENIGN TUMOR; BONE MARROW BIOPSY; CELL AGGREGATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; LARGE CELL LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MANTLE CELL LYMPHOMA; MEASUREMENT; OVARY FOLLICLE CELL; PROTEIN EXPRESSION; STAINING;

BIOPSY; BONE MARROW; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LYMPHOMA, B-CELL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 9644255700     PISSN: 08878013     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcla.20039     Document Type: Article

References (20)

1. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-1326.
2. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation study. Blood 1996;88:1046-1051.
3. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1994;69:135-139.
4. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998;58:5071-5074.
5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-921.
6. Ben-Ezra JM, King BE, Harris AC, Todd WM, Kornstein MJ. Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies. Mod Pathol 1994;7:560-564.
7. Granziero L, Ghia P, Circosta P, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-2783.
8. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-1136.
9. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315-5320.
10. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-584.
11. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-1240.
12. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93:1541-1552.
13. Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000;96:1921-1925.
14. Kuttler F, Valnet-Rabier MB, Angonin R, et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia 2002;16:726-735.
15. Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res 2001;21:595-600.
16. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-1542.
17. Sugawara M, Matsuzuka F, Fukata S, Kuma K, Moatamed F, Haugen BR. Excessive survivin expression in thyroid lymphomas. Hum Pathol 2002;33:524-527.
18. Garcia JF, Camacho FI, Morente M, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003;101:681-689.
19. Mori N, Yamada Y, Hata T, et al. Expression of survivin in HTLV-I-infected T-cell lines and primary ATL cells. Biochem Biophys Res Commun 2001;282:1110-1113.
20. Shinozawa I, Inokuchi K, Wakabayashi I, Dan K. Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies. Leuk Res 2000;24:965-970.